The independent source for health policy research, polling, and news.
101 - 120 of 465 Results
The story of MitraClip, a device Dr. Oz helped invent to treat faulty heart valves, is a cautionary tale about the science, business, and regulation of medical technology.
The Supreme Court has issued its final opinions for the 2023-24 term, including decisions affecting abortion access, the opioid epidemic, and how the federal government functions. In this special episode, Sarah Somers , legal director of the National Health Law Program, joins KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss how the justices disposed of the term’s health-related cases and what those decisions could mean going forward.
A Supreme Court ruling restricting federal power will likely have seismic ramifications for health policy. A flood of litigation — with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations they say are too expensive or burdensome and not authorized by law — could leave the country with a patchwork of disparate health regulations.
In what will certainly be remembered as a landmark decision, the Supreme Court has overruled a 40-year-old precedent that gave federal agencies, rather than judges, the power to interpret ambiguous laws passed by Congress. Administrative experts say the decision will dramatically change the way key health agencies do business. Also, the court decided not to decide whether a federal law requiring hospitals to provide emergency care overrides Idaho’s near-total ban on abortion. Alice Miranda Ollstein of Politico, Victoria Knight of Axios, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
The Supreme Court has dismissed a challenge to the FDA’s approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of KFF Health News, and Emmarie Huetteman of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF’s new “Health Policy 101” primer.
The nursing home industry — as well as a healthy number of Congress members — are all pushing back on the Biden administration’s new rules on nursing home staffing. Industry officials say that there are not enough workers to meet the requirements and that the costs would be prohibitive. Meanwhile, Democrats on Capitol Hill are trying to force Republicans to explain their exact positions on assuring access to contraceptives and in vitro fertilization. Rachel Cohrs Zhang of Stat, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” feature about a free cruise that turned out to be anything but.
June is when the Supreme Court typically issues rulings in the major cases it hears during that year’s term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, KFF’s Laurie Sobel, associate director for women’s health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.
Mounting evidence suggests psychoactive drugs including LSD, ketamine, mushrooms, and MDMA can be powerful treatments for severe depression and PTSD. But not everyone is convinced. And even if such drugs gain FDA approval, safety protocols could render them extremely expensive.
Federal regulations prevent gay and bisexual men from donating tissue, such as corneas, ligaments, and blood vessels. Similar restrictions have been relaxed or lifted for donated blood and organs in recent years.
Johns Dental Laboratories stopped making the Anterior Growth Guidance Appliance last year after a KFF Health News-CBS News investigation into allegations of patient harm. The company had “never” reported any complaints about its products to the FDA, according to the agency.
A decade after Congress told the FDA to expedite the approval of more effective sunscreens, the federal government still has not approved sunscreen ingredients that are safely being used around the world. Meanwhile, skin cancer is the nation’s most common cancer.
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
Cattle across the country are infected by the H5N1 bird flu. The virus isn’t spreading among people — but if it evolves to do that, fears of another pandemic could be realized.
A six-week abortion ban took effect in Florida this week, dramatically restricting access to the procedure not just in the nation’s third-most-populous state but across the South. Patients from states with even more restrictive bans had been flooding in since the overturn of Roe v. Wade in 2022. Meanwhile, the CEO of the health behemoth UnitedHealth Group appeared before committees in both the House and Senate, where lawmakers grilled him about the February cyberattack on subsidiary Change Healthcare and how its ramifications are being felt months later. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachana Pradhan of KFF Health News join KFF Health News’ Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Some pumps used in end-stage heart failure caused a buildup of biological material that blocks blood flow from the device to the heart’s aorta. The FDA’s recall affects nearly 14,000 devices.
Most of the doctors the FDA tapped to advise it on an Abbott medical device had financial ties to the company. The FDA didn’t disclose the payments.
The end goal for a conservative Christian group’s mifepristone case before the Supreme Court: a de facto nationwide abortion ban.
A pill form of an effective drug for postpartum depression hit the market in December, but most insurers do not yet have a policy on when or whether they will pay for it. The hurdles to obtain its predecessor medication have advocates worried.
The Environmental Protection Agency is tightening regulation of ethylene oxide, a carcinogenic gas used to sterilize medical devices. The agency is trying to balance the interests of the health care industry supply chain with those of communities where the gas creates airborne health risks.
© 2026 KFF